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FlAsH labellingThe interaction between ligands and the G protein-coupled receptors (GPCRs) to which they bind has long
been the focus of intensive investigation. The signalling cascades triggered by receptor activation, due in
most cases to ligand binding, are of great physiological and medical importance; indeed, GPCRs are targeted
by in excess of 30% of small molecule therapeutic medicines. Attempts to identify further pharmacologically
useful GPCR ligands, for receptors with known and unknown endogenous ligands, continue apace. In earlier
days direct assessment of such interactions was restricted largely to the use of ligands incorporating radioac-
tive isotope labels as this allowed detection of the ligand and monitoring its interaction with the GPCR. This
use of such markers has continued with the development of ligands labelled with ﬂuorophores and their
application to the study of receptor–ligand interactions using both light microscopy and resonance energy
transfer techniques, including homogenous time-resolved ﬂuorescence resonance energy transfer. Details
of ligand–receptor interactions via X-ray crystallography are advancing rapidly as methods suitable for
routine production of substantial amounts and stabilised forms of GPCRs have been developed and there is
hope that this may become as routine as the co-crystallisation of serine/threonine kinases with ligands, an
approach that has facilitated widespread use of rapid structure-based ligand design. Conformational changes
involved in the activation of GPCRs, widely predicted by biochemical and biophysical means, have inspired
the development of intramolecular FRET-based sensor forms of GPCRs designed to investigate the events
following ligand binding and resulting in a signal propagation across the cell membrane. Finally, a number
of techniques are emerging in which ligand–GPCR binding can be studied in ways that, whilst indirect, are
able to monitor its results in an unbiased and integrated manner. This article is part of a Special Issue entitled:
Structural and biophysical characterisation of membrane protein–ligand binding.
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1.1. Guanine nucleotide binding protein-coupled receptors (GPCRs)
GPCRs are the largest family of transmembrane proteins in the
human genome and their encoded genes make up a signiﬁcant propor-
tion of the genome devoted to cellular signalling. Indeed signalling via
GPCRs is one of themost important processes in the regulation of phys-
iological functions. GPCRs aremembrane-spanning polypeptideswhose
most notable structural feature is a serpentine arrangement of seven
sequential α-helices all of which cross from one face of the membraneCFP
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Fig. 1. Comparison of ﬂuorescence resonance energy transfer (FRET) with bioluminescence r
carboxy-termini of interacting GPCRs. Upon excitation with light at 430 nm the CFP emits lig
FRET signal. B. BRET1 based β-arrestin-2 recruitment assay. The Rluc tagged GPCR is activate
translocated to the membrane to interact with the receptor. This brings Rluc and Venus into
light at 480 nm this excites the Venus ﬂuorescent protein, which subsequently emits lightto the other to form transmembrane domains (TMD) with the amino-
terminus of the protein outside the membrane, whilst the carboxy-
terminus resides within the cytoplasm (Fig. 1). The function of these
receptors is to detect external (to the cell) stimuli and pass a signal
across the membrane to a cascade of other signallingmolecules to elicit
a physiological response. A wide range of external stimuli may be in-
volved ranging fromphotons to odorants, hormones, neurotransmitters
and lipids, and these vary in size from ions and small molecules to
peptides and proteins. It is the breadth of this range of stimuli which
makes GPCRs such important drug targets and, consequently, the
focus of much pharmacological research. Investigation of the humanFRETeYFP
uc coelenterazine h
esonance energy transfer (BRET). A. FRET between ﬂuorescent proteins attached to the
ht at 470 nm, which then excites the eYFP, causing the eYFP to emit light at 535 nm, the
d by ligand binding, causing β-arrestin-2 linked to the ﬂuorescent protein Venus to be
close proximity, and when Rluc catalyses the oxidation of coelenterazine h and emits
at 530 nm.
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that encode GPCRs, around 350 of which are predicted to generate
non-olfactory receptors [1]. The physiological function of many of
these is, as yet, unknown and they are termed orphan receptors. An
important part of GPCR research is the search for natural ligands that
regulate these orphan receptors in order to deﬁne their physiological
function [2].
GPCR research began with observations of physiological responses
to ligands in intact organisms or in preparations of organs or cell
types. This, together with the use of ligands able to block such
responses, resulted in classiﬁcation of receptors into groups deﬁned
by their pharmacology [3]. This phase of GPCR research was followed
by one in which biochemical techniques explored the details of
signalling processes and downstream pathways, whilst the cDNAs of
many GPCRs and other associated proteins were cloned and investi-
gated by a variety of means including visualisation in living cells by
the incorporation into their primary sequences of cDNAs encoding
ﬂuorescent proteins [4–7]. The determination of GPCR structures by
X-ray crystallography, however, was comparatively slow to develop
given the great signiﬁcance of the class of receptors and this reﬂects
the inherent difﬁculties of ﬁrstly purifying in soluble form and then
crystallising integral membrane proteins. The ﬁrst GPCR structure to
be solved was that of bovine rhodopsin, a light-activated GPCR,
which is the ﬁrst step in the signalling pathway leading to vision
[8]. This was the only GPCR structure available for some years and,
as a consequence, was the basis of a great deal of modelling to infer
and predict structural information for other GPCRs [9,10]. In recent
years, however, GPCR structures which were once thought obdurate
have begun to appear regularly in the literature. Examples include
the human β2 adrenergic receptor [11], human A2A adenosine recep-
tor (bound to an antagonist) [12], chemokine receptor CXCR4 (bound
to antagonists) [13], and μ, δ and κ opioid receptors (bound to antag-
onists) [14–16]. There has also been structural deﬁnition of a complex
between the β2 adrenergic receptor and its predominant interacting
partner, the Gsα subunit [17]. It seems likely that this progress is
set to continue, particularly taking into account the development of
thermostabilised receptors [18] and various other methodological
breakthroughs described in ref. [19]. Most of the known GPCR struc-
tures have been determined from crystals which have been grown
in the presence of receptor ligands, either agonists and antagonists,
to stabilise the receptor in an active or inactive conformation respec-
tively, which in turn has raised questions about conformational
changes that underpin such transitions of state. In a number of
cases, the unexpected observation has been that there are often rath-
er limited differences between the agonist- and antagonist-bound
forms, unless the appropriate G-protein α subunit is present within
the system, either in its entirety or as a fragment [19]. This has
revealed changes in the structures predicted largely from previous
biophysical and mutagenic studies [20] which suggested that GPCR
activation would involve an outward movement of trans-membrane
domain 6 (TMD6) and possible breakage of an ionic lock generated
with amino acids at the bottom of TMD3 [19]. Additional work is re-
quired to determine if this type of mechanism is generally applicable
to the other families of GPCRs that are unrelated to rhodopsin.
1.2. Receptor oligomerisation
GPCRs were, until comparatively recently, considered to exist and
to function as monomeric polypeptides and, indeed, recent work has
demonstrated that they are functional after puriﬁcation and reconsti-
tution as monomers in high density lipoprotein particles. Examples of
this include both the β2-adrenergic receptor [21] and the μ-opioid
receptor [22]. Such experiments notwithstanding, a large body of ev-
idence has built up over recent years to support the concept of recep-
tor oligomerisation, as reviewed in ref. [23–28]. A well characterised
example of receptor dimerisation/oligomerisation (which also hasimplications for trafﬁcking the receptor to the membrane) is that of
the type C GABAB (γ-aminobutyric acid) receptor which exists at the
cell membrane as an obligate heterodimer/heterotetramer consisting
of GABAB1 and GABAB2 subunits. The GABAB1 subunit is only able to be
trafﬁcked to the membrane if interacting with the GABAB2 subunit
as it contains an endoplasmic reticulum retention sequence in the
carboxy-terminal which is masked by the carboxy-terminal sequence
of the GABAB2 subunit. Additionally the GABAB subunits have further
complementary functions as the GABAB1 binds the ligand whilst
GABAB2 recruits and passes a signal to the G protein [29]. Subsequent
work has suggested that dimers of the GABAB receptor may interact to
form tetramers [30] or larger complexes and that this may regulate re-
ceptor signalling properties [31]. Despite this many questions regarding
receptor oligomerisation remain, not least of which is the relevance of
much of the work performed in engineered cell lines to receptor inter-
actions in more physiologically relevant situations.
1.3. Radioactive ligand binding
The use of radioactive ligand binding is central to the study of
GPCRs and their interactions with ligands and has been used for
many years. This technique provides a convenient and easy, (assum-
ing appropriate ligands are available, which will inherently not be the
case for orphan receptors) way to determine receptor expression
levels in both whole and broken cell formats and it is also used for
many pharmacological analyses including determination of binding
afﬁnities. However in recent years moves have been made to reduce
the use of radioactive isotopes (typically 3H and 125I) for reasons of
safety and the expense of radioactive waste disposal. Despite this,
for many uses, such as the determination of binding kinetic ‘on’ and
‘off’ rates, radioactive ligand binding remains an attractive and
frequently sole option. Alternative techniques such as that described
in Section 4, using an htrFRET approach based upon the use of a
donor-labelled SNAP-tagged receptor and a ligand tagged with an
htrFRET acceptor are becoming available [32], but still do not yet
quite match the versatility of radioactive ligand binding.
1.4. Label free techniques
In recent years a number of “label-free” techniques have been
developed to report interactions between ligand and receptor. This
has largely been driven by the needs of screening programmes
which aim to identify pharmacologically useful compounds from
chemical libraries and where there is a desire to capture concurrent
information on the totality of signals generated upon receptor activa-
tion. Examples of these platforms include CellKey™ (MDS Analytical
Technologies) and xCELLigence (Roche) systems, which measure
changes in electrical impedance across a cell monolayer as cells
alter their shape or move in response to receptor activation, and the
Epic® (Corning Incorporated) system which measures changes in
‘mass redistribution’ in response to similar receptor stimulation
[33–35]. An example of the use of the xCELLigence system was de-
scribed recently by Stallaert and colleagues [36] to dissect the contri-
butions of distinct elements of cellular response to the β2-adrenergic
receptor ligand isoproterenol. This study made use of pharmacologi-
cal inhibitors to identify Gi, Gs and Gβγ signalling events and to
identify the production of cAMP and the ERK1/2 pathways as
elements of the impedance response. Similar approaches employing
the Epic® system have shown that signals reﬂecting activation of
each of Gq, Gi, Gs and G13 can be observed and deconvoluted from a
complex overall pattern [37].
1.5. Resonance energy transfer techniques
The last 10–15 years have seen huge growth in the use of biophys-
ical techniques such as Resonance Energy Transfer (RET or Förster
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and also interactions between GPCRs and other proteins [38]. The
principal advantage of such approaches is that they are able to mon-
itor the close proximity and potential interactions between proteins
in living cells and so provide information distinct from conventional
biochemical techniques, such as co-immunoprecipitation. The growth
in the use of RET techniques has been fuelled by advances in both
optical instrumentation and the development, ﬁrst of variants of
the green ﬂuorescent protein (GFP), originally isolated from the
crystal jelly Aequorea victoria [39], and subsequently other suitable
ﬂuorophores. Among the ﬁrst variants of GFP to be developed were
the cyan ﬂuorescent protein (CFP) and yellow ﬂuorescent protein
(YFP) [40], forms which are able to function as an efﬁcient RET
donor/acceptor pair, though in many instances these have now been
superseded by the further development of a range of ﬂuorescent pro-
teins which have distinct excitation/emission spectra, higher quantal
yield and therefore brighter ﬂuorescence and which have been
engineered to be strictly monomeric in nature (an A206K mutation
for GFP derivatives) [41]. This latter feature is highly desirable as
wild type ﬂuorescent proteins often aggregate to form dimeric or
tetrameric complexes [42,43]. That the ﬂuorescent proteins should
be monomeric is clearly of great importance if they are being used
to study protein–protein interactions as a tendency to interact on
the part of the ﬂuorescent proteins themselves could result in false
positive results. RET involving transfer of energy between ﬂuorescent
proteins (such as from CFP, as a donor, to YFP, as an acceptor) is
known as ﬂuorescence resonance energy transfer (FRET) (Fig. 1A).
An alternative form of RET is Bioluminescence Resonance Energy
Transfer (BRET), which has becomewidely used to examine the inter-
actions between GPCRs and other proteins. A key example of work
employing BRET based techniques includes studies of the recruitment
of β-arrestins to interact with the inner membrane face of a GPCR
upon activation of the GPCR by an agonist ligand, a system widely
used in screening assays to identify novel activators of GPCRs [44].
In principle, BRET is similar to FRET, but rather than the energy
donor being a ﬂuorescent protein, the energy donor is a luciferase
type enzyme usually cloned from the Sea Pansy Renilla reniformis.
Here the donated energy is derived from the enzymatic oxidation of
a substrate by the luciferase which is then emitted as light, rather
than the excitation of a ﬂuorescent protein with light, which is then
re-emitted as light of a different wavelength (Fig. 1B).
RET, as described above, involves the transfer of energy from a
donor ﬂuorophore to an acceptor ﬂuorophore and in order for this
to happen there must be of the order of 30% or more overlap between
the emission spectrum of the donor and the absorption spectrum of
the acceptor [45]. In addition the distance between the donor and
acceptor and also their orientation with respect to one another are
important if RET is to occur. Considering the issue of distance ﬁrst,
for RET to be observed, the donor and acceptor ﬂuorophores must
be within the Förster radius (usually 3-6nm) and because the RET
efﬁciency reduces as a function of the inverse sixth power of the
separation [46], then it is only possible to generate a useful RET signal
if the donor and acceptor are 1–10 nm apart [46]. It is this level of
spatial resolution which is crucial for the interpretation that such
experiments are indicative of direct protein–protein interactions
between the partner proteins linked to the energy donor and acceptor
species. The relative orientation between the RET pair, that is the
orientation of emission and absorption dipoles (transitional dipole
moments) within the ﬂuorescent protein structure must be consid-
ered and must be orientated at an angle other then 90°. If this angle
is 90° then the RET signal will be abolished due to self cancelling os-
cillations. By contrast if the dipole moments are parallel then signals
will have the maximum value. A positive RET signal may be assumed
to be an indication that two proteins are in close proximity, but is not
proof of a direct interaction between them. Similarly, a negative
signal does not necessarily mean that there is no direct interactionbetween the proteins linked to the RET partners but may reﬂect
distance and relative orientation issues described above.
1.5.1. Fluorescence resonance energy transfer (FRET)
FRET is a form of RET in which energy transfer occurs between
ﬂuorophores according to the criteria described in the previous section.
This is often performed between two ﬂuorophores attached to different,
but putatively interacting proteins, known as intermolecular FRET
(Fig. 2A). An alternative possibility is intramolecular FRET which occurs
between two ﬂuorophores that have been incorporated into a single
protein, (Fig. 2B). In the former case the objective is to monitor the
interaction between the pair of proteins to which the ﬂuorophores are
attached, whilst in the latter, since the ﬂuorophores are “ﬁxed” within
the limits of the ﬂexibility of the protein intowhich they are incorporat-
ed, the intention is to monitor changes in the conformation of the
protein due to, for example, the binding of a ligand (see Section 3).
Clearly, in the case of intramolecular FRET equal expression of the two
ﬂuorophores is “built in”, whereas for intermolecular FRET additional
experiments are required to ensure equivalent expression.
FRET can be monitored in a number of different ways of which the
most commonly used are as follows: a) acceptor photobleaching
(after bleaching the acceptor with intense light, an increase can be
seen in donor emission, as energy is no longer being donated to the
acceptor); b) sensitised emission (the emission from the acceptor
due to energy transferred from the donor); and c) ﬂuorescent lifetime
decay (after excitation with a pulsed laser, donor ﬂuorescence decays
more rapidly with increasing FRET efﬁciency). In all cases appropriate
experimental controls are important to prevent artifactual results due
to bleed-through between the channels measuring the ﬂuorophore
emission or the quenching of donor or acceptor ﬂuorescence [47].
The development of FRET techniques has been rapid and of partic-
ular relevance to the study of GPCRs which has been the introduction
of homogenous time-resolved FRET (htrFRET). This is based upon the
use of lanthanide FRET donors, usually terbium, within a cryptate
cage. The advantage of this is that as a FRET donor the lanthanides ex-
hibit long lived ﬂuorescence. This allows FRET to be measured after a
time delay during which the background ﬂuorescence, common to all
excited biological systems, decays and therefore this greatly increases
the signal to background window. This temporal selectivity, together
with good spectral compatibility of the donor and acceptor and the
lack of polarisation of the lanthanide emission (resulting in only
weak dependence of htrFRET upon the relative orientation of donor
and acceptor) ensures that htrFRET has the ability to deliver
improved signal to noise ratio than alternative FRET techniques [27].
Early experiments using this approach to monitor δ-opioid receptor
homodimerisation employed donor and acceptor htrFRET ﬂuorophore-
labelled antibodies that bind speciﬁcally to receptors tagged with the
c-Myc and FLAG peptide epitopes [48]. This basic approach was subse-
quently adopted to demonstrate homodimerisation of the α1A- [49]
and α1B- [50] adrenergic receptors and heterodimerisation between
each of the GABAB1–GABAB2 receptor subunits [51] and chemokine
CXCR1–CXCR2 receptors [52]. However, the use of antibodies linked
to donor and acceptor ﬂuorophores has potential disadvantages, includ-
ing their large sizewhich could result in steric hindrance and their biva-
lent naturewhichmight intrinsically drive or contribute to the observed
interactions. Themain advantages are based on the speciﬁc high afﬁnity
interaction between the antibody and epitope tag, which allows the
antibody to be used at a relatively low concentration and that the
approach can be used directly in native cells, provided appropriate
antibodies to the extracellular domains are available, as in the case of
many ‘cluster of differentiation’ (CD) proteins used to deﬁne speciﬁc
cell populations in immunological research [53,54].
An alternative to the use of antibodies for the addition of htrFRET
donor and acceptor ﬂuorophores is the use of a ‘self-labelling’ protein
that behaves as a ‘suicide enzyme’. Such systems include the ‘SNAP’
tag. This is a 23 kDa protein, based upon the DNA repair enzyme
FRETCFP eYFP
FRETCFP eYFP
A
B
Fig. 2. Principle of intermolecular and intramolecular FRET. A. Two co-expressed GPCRs labelled with carboxy-terminal eYFP and CFP ﬂuorescent protein tags. If these interact, the
tags are brought into close proximity and intermolecular FRET can then occur. B. A GPCR tagged with CFP in the third intracellular loop and eYFP at the carboxy-terminal, emits an
intramolecular FRET signal, which can then be modiﬁed by conformational changes in the receptor in response to ligand binding.
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benzylguanine derivative substrate that incorporates a suitable
ﬂuorophore hence transferring theﬂuorophore-linked benzyl group co-
valently and irreversibly onto the ‘SNAP’ protein (Fig. 3A). This, along-
side the similar but non cross-reacting ‘CLIP’ tag (Fig. 3B), provides
the basis of the Tag-lite™ system (CisBio Bioassays) which allows cells
expressing proteins in which their extracellular domains have been
modiﬁed to encode the ‘SNAP’ and/or ‘CLIP’ tags to be simultaneously
labelled with htrFRET donor and acceptor species. This system has
been used to study GPCR oligomerisation in a number of examples of
both homo- and hetero-conﬁgurations [30,55–57].
2. Fluorescently-labelled ligands; applications and uses
GPCR ligands that have beenmodiﬁed to include a ﬂuorophore have
been in use for more than 30 years and have been applied in a wide
range of analyses designed to examine aspects of GPCR localisation,
internalisation, pharmacology and function, as reviewed in [58–61].
Speciﬁc examples include the use of the orexin OX1 receptor agonist
oxerin A linked to TAMRA (carboxytetramethylrhodamine) to monitor
the internalisation of the receptor and its interaction with β-arrestin-2
linked to GFP [62] and the use of ﬂuorescent adrenoceptor and cannabi-
noid ligands to examine receptor distribution in small arteries [63].
Fluorescent derivatives have been made for both peptide and small
molecule ligands, initially without detailed analysis of the effect thatthe ﬂuorophore might have on the pharmacology of the ligand at its
cognate GPCR. Subsequently the design of ﬂuorescent ligands has be-
come a much more thoughtful process as described in refs. [60,64],
with detailed analysis of such behaviours being deﬁned prior to func-
tional application.
A number of applications for ﬂuorescent ligands have recently
emerged in which FRET is generated between a receptor-attached
ﬂuorophore and a bound ﬂuorescent ligand. Albizu and co-workers
used novel ﬂuorescent vasopressin and oxytocin receptor ligands in
conjunction with ﬂuorophore-labelled antibodies speciﬁc to a receptor
N-terminalHA (inﬂuenza hemagglutinin) tag to develop a ligand screen.
Herein, positive ‘targets’ competed with the ﬂuorescent ligand and so
reduced the FRET signal allowing the identiﬁcation of novel ligands
and the investigation of their pharmacology [65]. Subsequently, similar
studies have been performed using receptors with N-terminally fused
ﬂuorescent proteins as the second FRET component. Examples include
the identiﬁcation of ligands for the growth hormone secretagogue type
1a [66] and vasopressin V2 receptors [67]. The latter study also described
FRET experiments performed to demonstrate vasopressin V1A–V2 cell
surface heterodimerisation using the selectivity of ligands labelled
with FRET donor and acceptor. The mechanism of receptor ligand bind-
ing to the muscarinic M1 acetylcholine receptor has also been investi-
gated using such an approach [68,69].
A potentially important and powerful application of FRET between
ﬂuorescent ligands and a labelled receptor was described by Zwier
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Fig. 3. SNAP and CLIP labelling; the Tag-lite htrFRET system. A. Amino-terminally SNAP tagged GPCR reacts with O6-benzylguanine-Lumi4Tb, irreversibly labelling the SNAP tag
with the Taglite htrFRET donor, Lumi4Tb. B. Simultaneously, an amino-terminally CLIP-tagged GPCR reacts with O6-benzylcytosine-RED and is hence labelled with a Taglite htrFRET
acceptor. C. An htrFRET signal can then be generated between the donor and acceptor, should they be in sufﬁciently close proximity.
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a htrFRET donor (see Section 1.5.1) and a FRET acceptor-labelled ligand
was then added, generating an htrFRET signal (Fig. 4). This is a highly
adaptable techniquewhich can bemodiﬁed for screening, the investiga-
tion of the kinetics of ligand binding and a host of other pharmacologi-
cal analyses. However it is dependent upon the use of a ‘SNAP’-taggedreceptor (which can be easily generated) and the availability of an
appropriate htrFRET labelled ligand.
The technique of ﬂuorescence anisotropy is also one which makes
use of ﬂuorescently-labelled ligands, and is based upon the property
that light emitted by a ﬂuorophore does not have the same intensity
along all axes of polarisation. The ﬂuorescence anisotropy signal is
FRET
TM1 TM2 TM3
TM4 TM5
TM6
TM7
SNAP
LIGAND
Lumi 4Tb
Taglite
acceptor
Fig. 4. HtrFRET between an amino-terminal SNAP-tagged receptor and an htrFRET acceptor labelled ligand An amino-terminal SNAP-tagged GPCR labelled with the Taglite htrFRET
donor, Lumi4Tb, binds a ligand labelled with a Taglite acceptor. The htrFRET signal can be used in a similar way as radioactive ligand binding to investigate the receptor–ligand
interaction.
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ligand and one bound to a (much larger) receptor. Thus, when irradi-
ated with plane-polarised light the rapidly rotating free ligand
ﬂuorophore emits highly depolarised light, whereas for ligand bound
to a receptor (and rotating more slowly) the degree of depolarisation
of the emitted light is less. Therefore, by monitoring the polarisation
of the emitted light it is possible to assess the level of binding of a ﬂuo-
rescent ligand to a receptor. This technique was recently compared to a
traditional radio-ligand binding approach for the muscarinic M1 recep-
tor by Huwiler and co-workers [70] and found to give similar IC50
values. Fluorescence anisotropy has also been used by Woll and col-
leagues [71] to monitor the binding of ﬂuorescently labelled peptides,
as opposed to small molecule ligands.
3. Monitoring GPCR activation in response to ligand: the
FRET sensor
The basis of monitoring ligand-induced GPCR activation by intra-
molecular FRET is that ligand binding induces small conformational
changes within the GPCR around the ligand binding site, which are
then ampliﬁed to become larger movements at the cytoplasmic face
of the receptor, in turn transmitting a signal to (usually) a G protein.
This movement at the cytoplasmic face of the activating receptor is
generally considered to be a change in position of TMD6 in relation
to TMD3. As noted above, this view of receptor activation was devel-
oped from use of a variety of biophysical techniques [72] and has now
been validated by some of the recently reported GPCR crystal struc-
tures [19,20]. Consequently the idea behind an intramolecular GPCR
FRET sensor is that a FRET signal is generated from two appropriate
ﬂuorophores incorporated into the structure of the GPCR in such a
way that a change in conformation alters the relative position of the
ﬂuorophores and hence alters the FRET signal.
The ﬁrst experiments of this type were performed by Kobilka and
colleagues and involved incorporating ﬂuorescent labels into puriﬁed
human β2 adrenergic receptor and then using ﬂuorescence spectroscopy
to determine changes in the environment of theﬂuorescent label [73,74].It was found that concentration–response curves to a full agonist
(isoproterenol) could be generated and that such changes in ﬂuores-
cence could be blocked by β-adrenergic antagonists. Furthermore,
using a series of agonists with different levels of efﬁcacy, a correlation
was observed between changes in ﬂuorescence and pharmacological
efﬁcacy [73]. Subsequently the β2 adrenergic receptor was mutated to
remove certain cysteine residues (the binding site of the ﬂuorescent
probe) and itwas found that cysteines in TMD3andTMD6were essential
for ligand-induced modulation of ﬂuorescence [74]. This approach was
reﬁned further by the use of a ﬂuorescence quenching reagent [75],
which indicated movement of TMD6, and demonstrated that different
agonists produce differences in the kinetics of movement [76].
The use of FRET (as opposed to ﬂuorescence quenching) in exper-
iments of this type was described by Granier [77] and again involved
the puriﬁed β2-adrenergic receptor, mutated to include a FlAsH
(Fluorescein Arsenical Hairpin binder) binding sequence (CCPGCC)
at two alternative positions in the C-terminus. These bound the
ﬂuorophore FlAsH, which then acted as a FRET donor. The FRET ac-
ceptor was Alexa Fluor 568 maleimide and this reacted with cysteine
265 in intracellular loop 3 (IL3) of the receptor close to the cytoplas-
mic end of TMD6. The FRET signal from this labelled receptor was
used to calculate the distances between the alternative donors and
the acceptor and also to demonstrate ligand speciﬁc changes in the
FRET signal.
Thus, such experiments using puriﬁed receptors were able show
that receptor activation involves conformational changes such as
the movement of TMD6 and that different agonists produce speciﬁc
conformational changes. The use of puriﬁed receptors however is
not ideal or indeed always possible. Consequently the focus of such
receptor “sensor” experiments has largely moved to the use of live
cells expressing receptor constructs which incorporate ﬂuorescent
proteins, or a peptide sequence capable of being labelled in situ, as
part of the primary sequence. This approach was ﬁrst described by
Vilardaga [78] using the parathyroid hormone receptor (PTHR) and
α2A-adrenergic receptor. Constructs were generated with CFP and
YFP fused into the primary sequence of the third intracellular loop
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the α2A-adrenergic receptor (Fig. 5A). These constructs were desig-
nated “cameleons” based on previous efforts to generate sensors sen-
sitive to alterations in cellular Ca2+ levels. Despite the addition of two
approximately 30kDa ﬂuorescent proteins into their sequence, the
GPCR variants were found to exhibit typical ligand binding character-
istics, albeit with reduced afﬁnity for certain ligands, to be expressed
at the cell surface in the same way as the unmodiﬁed receptors, and
to possess broadly similar signalling characteristics as the wild type
protein. The FRET signal obtained after treatment with agonist was
reduced (compared to the untreated) by 15% for the PTHR sensor
and by 5% for the α2A-adrenergic receptor sensor. In both cases,
the rapid kinetics that would be expected from the physiologicalmGluR5 sigVSV-G
mGluR5 siVSV-G
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may indicate a more complex binding process of the peptide
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agonist-induced FRET change represented a valid reﬂection of recep-
tor activation. This was characterised in a number of ways. For exam-
ple, to preclude the possibility that the FRET change was due to
interaction with a downstream signalling molecule such as a G
protein or a β-arrestin, FRET experiments were performed using
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Modiﬁed from [85].
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ripheral membrane proteins were removed or denatured by treatment
with urea. Additionally, treatment of cells expressing theα2A-adrenergic
receptor sensor with pertussis toxin (which prevents receptor interac-
tions with Gi/Go subunits by catalysing an ADP-ribosylation reaction)
was without effect upon the agonist-dependent change in FRET signal.
To show that the FRET change did indeed require agonist binding
Vilardaga and co-workers used an antagonist to the PTHR which was
unable to induce any change in the FRET signal [78]. Thus antagonist
ligands were able to bind, but not activate the receptor and caused no
modulation of the FRET signal when added alone. Finally, because a
bound G protein is known to promote the active, agonist bound state
of the receptor, experiments were carried out in which puriﬁed Goα
subunit was added tomembranes expressing theα2A-adrenergic recep-
tor sensor, whichwere then treatedwith a sub-saturating concentration
of the agonist UK14,304. This resulted in a change in FRET due to promo-
tion of the active state byGoα binding and thiswas signiﬁcantly reduced
by the addition of the poorly hydrolysed GTP analogue, GTPγS which
results in G protein activation. Thus the change in FRET signal produced
by these constructs upon agonist treatment appeared to mirror effects
known to be produced by the receptor moving from an inactive to an
active state.
Since these early experiments a number of other sensors of this
type have been constructed for class A GPCRs, examples of which
include bradykinin B2 [79], β1-adrenergic [80], β2-adrenergic [81]
and a distinct parathyroid hormone receptor sensor made using the
ﬂuorescent proteins Cerulean (FRET donor) and Citrine (FRET accep-
tor) [82]. A perhaps surprising aspect of many of these constructs was
the similarity of their behaviour to the unmodiﬁed receptors. Given
that third intracellular loop of many receptors plays a key role in
G-protein interactions it is perhaps surprising that more variation in
signalling behaviour has not been seen routinely. In order to identify
and potentially limit the effects of the insertion of a ﬂuorescent pro-
tein into the third intracellular loop of a receptor [83], comparisons
were undertaken using FRET sensors constructed from the human
A2A adenosine receptor with CFP and YFP inserted into the third intra-
cellular loop and carboxy-terminus respectively, with one in which
CFP was inserted into the carboxy-terminal and the much smaller
FlAsH sequence (CCPGCC, as described above) in the third intracellu-
lar loop (Fig. 5B). Herein CFP acted as FRET donor and FlAsH-labelled
CCPGCC as the FRET acceptor. It was found that the CFP–YFP based
sensor was able to generate a FRET signal corresponding to receptor
activation, but was unable to couple to the downstream effector
adenylyl cyclase. By contrast, however, the CFP–FlAsH version of
the sensor was able to change the agonist-activated FRET signal by
5-fold, whilst retaining comparable kinetics and downstream signal-
ling as the CFP-YFP sensor [83]. Hoffmann and co-workers also
found that this was true for the mouse α2A-adrenergic receptor
[83]. It appears, therefore, that utilising the FlAsH sequence and labelling
can be advantageous in that it minimises possible disruption to the
receptor structure and function, probably because the tetracysteine–
biarsenical tag is much smaller than a ﬂuorescent protein (the use
and optimisation of the FlAsH binding sequence and its associated
ﬂuorophore (commercially available as TC-FlAsH, previously known as
Lumio Green) is described in [84–87] together with other similar but
alternatively coloured reagents).
A number of other FRET biosensors incorporating the CFP-FlAsH
FRET pair were subsequently described for a variety of receptors in-
cluding the β2-adrenergic receptor [88], muscarinic M1, M3 and M5
receptors [89], the muscarinic M2 receptor [90] and the orexin OX1
and OX2 receptors [91]. The development of all of these sensors was
a more complex process than simply inserting the FlAsH sequence
into the third intracellular loop of the receptor at random and fusing
a CFP variant to the C-terminal tail. In most cases considerable opti-
misation of the positioning of the FlAsH sequence was required to
maximise the subsequent alteration in FRET signal upon addition ofan agonist and to ensure that the sensor was expressed effectively at
the cell membrane. This is well illustrated by reference to the work of
Xu and colleagues [91] describing the development of FRET sensors for
the orexin OX1 and OX2 receptors. To generate the OX1 sensor, the CFP
FRET donorwas added to the full length carboxy-terminal, or to versions
of the receptor with truncated carboxy-terminal sequences (from
wild-type length, 65 amino acids to 40 or 30 amino acids). The sequence
FLNCCPGCCMEP, (containing the minimal FlAsH binding sequence
CCPGCC), was introduced into the third intracellular loop, as either a re-
placement of 12wild-type amino acids tomaintain the loop length or to
replace 34 residues to shorten the loop from 59 to 36 amino acids. This
replacement occurred at the “centre” of the loop, however constructs
were also made in which the 34 amino acids were replaced at either
end of the loop sequence, that is close to either TMD5 or TMD6. Finally,
the amino-terminus of the receptor was modiﬁed with addition of an
mGluR5 signal sequence (MVLLLILSVLLLKEDVRGSA, [92]) to ensure ef-
fective delivery to the plasma membrane. Stable, antibiotic-controlled
inducible cell lines were generated for these constructs and it was
found that the greatest change in FRET upon addition of the peptide ag-
onist orexin A was produced by cells harbouring a sensor with a full
length carboxy-terminal tail and the FlAsH sequence placed in the mid-
dle of a shortened third intracellular loop. This sensor displayed a reduc-
tion in the FRET signal upon agonist treatment (consistent with the
activation process involving an increase in the distance between the
carboxy-terminal and the third intracellular loop), which was depen-
dent on the concentration of agonist applied (Fig. 6A) and blocked in
the presence of antagonist ligands (Fig. 6B). The change in FRET was
comparatively slow, (something also noted for the PTH receptor sensor
described above) and it may well be that this again reﬂects a more
complex, multi-step binding process between a receptor and a peptide
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The orexin OX2 sensor was generated in a similar manner to that of the
OX1, thus the CFP donor was fused to the full length carboxy-terminal
(78 amino acids) or a truncated version (60 amino acids) and the
FlAsH sequence introduced into the third intracellular loop, replacing
12 amino acids to maintain the length of the loop at 57 or replacing 28
amino acids to shorten the loop to 40. It was found that the greatest
alteration in FRET signal was produced by a sensor with both the trun-
cated carboxy-terminal and the shortened third intracellular loop. Con-
sequently it can be seen that considerable trial and error is involved in
the development of a successful FRET sensor and it should be noted
that, at least in the case of the orexin receptor constructs, much of the
screening had to be carried out after production of inducible stable cell
lines, rather than via transient transfection, in order for the sensors to
be efﬁciently expressed at the cell membrane. It should also be noted
that Xu and co-workers [91] performed awide range of studies to ensure
that the pharmacological and signalling characteristics of the FRET
sensors were very similar to those of the wild-type orexin receptors.
A useful application for FRET sensors of the type described above
has been the study of allosteric modulators of GPCR ligand activation.
These are ligands, ranging from small molecules to peptide and
protein toxins, which bind to sites distinct from the normal (endoge-
nous) ligand binding site (orthosteric site) and modulate (either
positively or negatively) the effect of agonist or inverse agonist li-
gands. This concept has been reviewed extensively in refs. [93–96].
The use of a FRET sensor in the investigation of allosteric modulators
of the muscarinic M2 receptor was described by Maier-Peuschel in
ref. [90] and involved the use of a receptor with CFP fused to the
carboxy-terminal and a FlAsH binding sequence in the third intracel-
lular loop. This FRET sensor displayed a reduced FRET signal on treat-
ment with orthosteric agonists, which was restored by removal of
the agonist or addition of antagonist. The allosteric ligands studied
(gallamine and dimethyl-W84), which caused no sensor response
when administered alone, were able to modulate markedly the effect
of agonist and to do so with kinetics much faster than the response to
an orthosteric antagonist, suggesting that they act by inducing a
receptor conformation which has reduced afﬁnity for the agonist.
4. FRET between ﬂuorescent ligands and the detection of
endogenously expressed receptor complexes
The concept of receptor dimerisation or oligomerisation is one for
which extensive evidence has been generated in studies performed in
cell systems heterologously expressing GPCRs (see Section 1.2).
Numerous examples of modiﬁed receptor pharmacology in cells
expressing pairs of receptors have been described and interpreted
as reﬂecting their heterodimerisation. However, much less data is
available in native cells and tissues. This is a substantial challenge as
the primary sequence modifying receptor labels and tags essential
to the techniques described above are not available or that such
modiﬁed receptors must be expressed transgenically. One potentially
attractive approach is the use of ﬂuorescently-labelled antibodies as
they can provide speciﬁcity and be of high afﬁnity. However, develop-
ing high quality antibodies to GPCRs has generally been challenging.
In addition, the size of antibodies and their bivalent nature raises
questions regarding both the effects of steric hindrance and the
possibility of dimerisation actually being driven by the addition of an-
tibody, rather than monitored by it. A recently described novel ap-
proach is that of measuring FRET between receptor ligands labelled
with FRET-competent ﬂuorophores. This was ﬁrst demonstrated by
using ﬂuorescently labelled ligands of the vasopressin V1A, V2 and do-
pamine D2 receptors, in a heterologous expression system [97,98].
The ﬂuorophores used were designed for htr-FRET measurements.
Within these studies the authors demonstrated, using htrFRET com-
petent ﬂuorophore-labelled oxytocin receptor ligands, that oxytocin
receptor multimers can be detected in prepared membranes preparedfrom and intact patches of native lactating rat mammary gland tissue.
This approach offers broad applicability, assuming that suitable
ligands can be prepared. It must be noted, however, that these exper-
iments were performed using tissue expressing levels of the oxytocin
receptor, (1–3 pmol·mg protein−1, [97]), comparable to those used
in many heterologous expression system studies and a challenge in
moving forward will be to both deﬁne and then lower the limits of
detectability of such signals to allow receptor complexes expressed
at much lower levels to be identiﬁed.5. Conclusions
The identiﬁcation and analysis of novel (and pharmacologically
useful) GPCR ligands, together with the further analysis of those
which are already known, are of great importance and, as such, the
focus of much effort. Many drugs that are in present use act via
GPCRs and its reasonable to assume that the effort to deorphanise
those GPCRs whose endogenous ligands are as yet unknown will
result in further potential drugs targets. The ﬂuorescence based tech-
niques described here to study the interactions between ligands and
GPCRs will be an important part of this. Clearly the screening of
compound libraries against GPCRs, as part of the search for new
drugs, requires readouts which are amenable to “high throughput”
screening and as such, FRET and ﬂuorescent labelling techniques
provide assay platforms which are homogeneous and which can be
scaled down in volume for economy both ﬁnancial and in terms of
the number of assays which can be carried out “per plate”.
Once new GPCR ligands are identiﬁed then ﬂuorescent labelling
and htrFRET can be used in place of the traditional radio-labelling
approach for the study of their binding and its effects upon the inter-
actions between the GPCR and other ligands. Subsequently, the trans-
duction of a ligand induced signal by a GPCR can be analysed using a
receptor modiﬁed as a FRET sensor.References
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